SpringerLink
Log in

Hormonersatztherapie

  • Chapter
Therapiehandbuch Gynäkologie und Geburtshilfe

  • 4987 Accesses

Zusammenfassung

Weitgehend zeitgleich mit dem Sistieren der ovariellen Östradiolproduktion erleben ca. 70% der Frauen mittelschwere bis schwere vasomotorische, psychische und somatische Beschwerden, die sich durch eine Östrogenbehandlung lindern oder häufig völlig beseitigen lassen. Gleichzeitig nehmen nach der Menopause prognostisch wichtige Erkrankungen wie Osteoporose und Herzinfarkte z. T. exponentiell zu. Nach dem Ergebnis von Beobachtungsstudien kann dies durch eine frühzeitige Östrogenbehandlung verhindert werden.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

Literatur

  • Barrett-Connor E, Grady D (1998) Hormone replacement therapy, heart disease, and other considerations. Annu Rev Public Health 19:55–72

    Article  PubMed  CAS  Google Scholar 

  • Beckmann M (federführend); Deutsche Gesellschaft für Gynäkologie und Geburtshilfe – DGGG (2004) Leitlinie DGGG. Konsensusempfehlungen zur Hormontherapie im Klimakterium und in der Postmenopause. Geburtsh Frauenheilkd 64: 1024–1028

    Article  Google Scholar 

  • Beckmann MW, Jud S, Kreienberg R. Standards (2010) Leitlinien und Richtlinien und das tägliche medizinische Handeln. Qualitätssicherung in der Frauenheilkunde. Frauenarzt 51:1134–1141

    Google Scholar 

  • Berat V et al. Million Women Study Collaborators (2003) Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 363: 419–427

    Google Scholar 

  • Berat V et al. Million Women Study Collaborators (2005) Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 365: 1543–1551

    Article  CAS  Google Scholar 

  • Birkhäuser M, Braendle W, Kuhl H, Mueck AO, Neulen J, Thaler CJ (Zürcher K (2010) 43. Arbeitstreffen. Empfehlungen zur Hormontherapie mit Estrogenen und Gestagenen im Klimakterium und in der Postmenopause. J Gynäkol Endokrinol 20: 12–19

    Google Scholar 

  • Brincat M, Galea R, Muscat Baron Y (1995) Menopausal connective tissue changes and Alzheimer« disease. Eur Menopause J 2(Suppl 1): 31–35

    Google Scholar 

  • Bühling K, Mueck AO (2010) HRT bei metabolischem Syndrom. CME Prakt Fortbild Gynäkol Geburtsmed Gyn Endokrinol 3: 172–184

    Google Scholar 

  • Bush TL, Whiteman M, Flaws JA (2001) Hormone replacement therapy and breast cancer: a qualitative review. Obstet Gynecol 98:498–508

    Article  PubMed  CAS  Google Scholar 

  • Canonico M et al. for the ESTHER Study Group (2006) Obesity and risk of venous thromboembolism among postmenopausal women: differential impact of hormone replacement therapy by route of estrogen administration. J Thromb Haemost 4: 1259–1265

    Article  PubMed  CAS  Google Scholar 

  • Canonico M et al. (for the ESTHER Study Group) (2007) Hormone therapy and venous thromboembolism among postmenopausal women. Impact of the route of estrogen administation and progestogens. Circulation 115: 840–845

    Article  PubMed  CAS  Google Scholar 

  • Canonico M, Alhenc-Gelas M, Plu-Bureau G et al. (2010a) Activated protein C resistance among postmenopausal women using transdermal estrogens: importance of the progestogen. Menopause 17(6): 1122–1127

    Article  Google Scholar 

  • Canonico M, Fournier A, Carcaillon et al. (2010b) Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism. Results from the E3N Cohort Study. Thromb Vasc Biol 30:340–345

    Article  CAS  Google Scholar 

  • Canonico M, Plu-Bureau G, Lowe GDO, Scarabin P-Y (2008) Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: a systematic review and meta-analysis. BMJ 336:1227–1231

    Article  PubMed  Google Scholar 

  • Cardozo I, Bachmann G, McClish D et al. (1998) Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: Second report of the Hormones and Urogenital Therapy Committee. Obstet Gynecol 92:722–727

    Article  PubMed  CAS  Google Scholar 

  • Chan JA, Meyerhardt JA, Chan AT et al. (2006) Hormone replacement therapy and survival after colorectal cancer diagnosis (Nurses Health Study). J Clin Oncol 24:5680–5686

    Article  PubMed  CAS  Google Scholar 

  • Chen WY et al. (2006) Unopposed estrogen therapy and the risk of invasive breast cancer. Nurses Health Study. Arch Intern Med 166:1027–1032

    Article  PubMed  CAS  Google Scholar 

  • Clarke CA, Glaser SL (2006) Recent declines in hormone therapy utilization and breast cancer incidence: Clinical and population-based evidence. J Clin Oncology 24:349–350

    Article  Google Scholar 

  • Cogliano V et al. (2005) Carcinogenicity of combined oestrogen-progestagen contraceptives and menopausal treatment. Lancet Oncol 6:552–553

    Article  PubMed  Google Scholar 

  • Collaborative Group on Hormonal Factors in Breast Cancer (1997) Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52.705 women with breast cancer and 108.411 women without breast cancer. Lancet 350:1047–1059

    Article  Google Scholar 

  • Cummings SR et al. (2008) LIFT Trial Investigators. The effects of tibolone in older postmenopausal women. N Engl J Med 359:697–708

    Article  PubMed  CAS  Google Scholar 

  • Lauzon-Guillain B de, Fournier A, Fabre A et al. (2009) Menopausal hormone therapy and new-onset diabetes in the French E3N cohort. Diabetologica 52:2092–2100

    Article  Google Scholar 

  • Dietel M, Lewis MA, Shapiro S (2005) Hormone replacement therapy: pathobiological aspects of hormone-sensitive cancers in women relevant to epidemiological studies on HRT: a mini-review. Hum Reprod 20:2052–2060

    Article  PubMed  CAS  Google Scholar 

  • Eicher W, Mueck AO (1994) Normalität oder Krankheit – Beschwerden der Wechseljahre. Sexualmedizin 10:276–279

    Google Scholar 

  • Eicher W, Mueck AO (1996) Die Behandlung östrogenmangelinduzierter Sexualstörungen. Gynäkol Geburtsh Rundschau 36: 83–89

    Article  CAS  Google Scholar 

  • EMAS (2008) European Menopause and Andropause Society) The EMAS 2008 update on clinical recommendations on postmenopausal replacement therapy. Maturitas 61:227–232

    Article  CAS  Google Scholar 

  • Ettinger B, Ensrud KE, Wallace R et al. (2004) Effects of ultralow-dose transdermal estradiol on bone mineral density: a randomized clinical trial. Obstet Gynecol 104:443–451

    Article  PubMed  CAS  Google Scholar 

  • Fantl JA, Cardozo LA, McClish DK and the Hormones and Urogenital Therapy Committee (1994) Estrogen therapy in the management of urinary incontinence in postmenopausal women: a meta-analysis. First report of the Hormones and Urogenital Therapy Committee. Obstet Gynecol 83:112–128

    Google Scholar 

  • Farquhar CM et al. (2004) Long-term hormone therapy for perimenopausal and postmenopausal women. Cochrane Library Rev Issue 3

    Google Scholar 

  • Farquhar CM et al. (2008) Long-term hormone therapy for perimenopausal and postmenopausal women. New search for studies completed, conclusions not changed. Cochrane Library Issue 4

    Google Scholar 

  • Fournier A, Berrino F, Clavel-Chapelon F (2008a) Unequal risks for breast cancer associated with different hormone therapies: results from the E3N cohort study. Breast Cancer Res Treat 107:103–111

    Article  CAS  Google Scholar 

  • Fournier A, Fabre A, Mesrine S et al. (2008b) Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor-defined invasive breast cancer. J Clin Oncology 26:1260–1268

    Article  Google Scholar 

  • Garbe E, Levesque L, Suissa S (2004) Variability of breast cancer risik in observational studies of hormone replacement therapy: a meta-regression analysis. Maturitas. J Eur Menopause Soc 47:175–183

    CAS  Google Scholar 

  • Garbe E, Suissa S (2004) Issues to debate on the Women’s Health Initiative (WHI) study. Hormone replacement therapy and acute coronary outcomes: methodological issues between randomized and observational studies. Human Reprod 19:8–13

    Article  CAS  Google Scholar 

  • Glazier G, Bowman MA (2001) A review of the evidence for the use of phytoestrogens as a replacement for traditional estrogen replacement therapy. Arch Intern Med 161:1161–1172

    Article  PubMed  CAS  Google Scholar 

  • Gohlke-Bärwolf C, Regitz-Zagrosek V, Mueck AO, Strasser RH (für die Deutsche Gesellschaft für K (2002) Stellenwert der Hormonersatztherapie zur Prävention der Koronaren Herzerkrankung bei Frauen. Z Kardiol 91:430–435

    Article  PubMed  Google Scholar 

  • Grady D, Gebretsadik T, Kerlikowski K, Ernster V, Petitti D (1995) Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol 85:304–315

    Article  PubMed  CAS  Google Scholar 

  • Grady D, Herrington D, Bittner R et al. (2002) Cardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen/progestin Replacement Study Follow-up (HERS II). JAMA 288:49

    Article  PubMed  Google Scholar 

  • Grady D, Rubin SM, Petitti DB et al. (1992) Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Int Med 1016–1037

    Google Scholar 

  • Greiser CM, Greiser EM, Dören M (2005) Menopausal hormone therapy and risk of breast cancer: a meta-analysis of epidemiological studies and randomized controlled trials. Human Reprod Update 11:561–573

    Article  CAS  Google Scholar 

  • Grodstein F, Manson JE, Stampfer MJ (2006) Hormone therapy and coronary heart disease: The role of time since menopause and age of hormone initiation. J Women’s Health 15: 35–44

    Article  Google Scholar 

  • Grodstein F, Manson JE, Stampfer MJ, Rexrode K (2008) Postmenopausal hormone therapy and stroke. Arch Intern Med 168:861–866

    Article  PubMed  CAS  Google Scholar 

  • Grodstein F, Newcomb PA, Stampfer MJ (1999) Postmenopausal hormone therapy and the risk of colorectal cancer: a review an meta-analysis. Am J Med 106:574–582

    Article  PubMed  CAS  Google Scholar 

  • Hanke H, Hanke S, Ickrath O et al. (1997) Estradiol concentrations in premenopausal women with coronary heart disease. Coronary Artery Dis 8:511–515

    CAS  Google Scholar 

  • Hauser GA, Huber P, Keller J, Lauritzen C, Schneider HPG (1996) Evaluation der klimakterischen Beschwerden (Menopause Rating Scale, MRS). Zentralbl Gynakol 116:15–23

    Google Scholar 

  • Heinemann LAJ (2004) WHI-Studie und Million Women Study aus epidemiologischer Sicht. Frauenarzt 45:217–222

    Google Scholar 

  • Henderson KD, Duan L, Sullivan-Halley J et al. (2010) Menopausal hormone therapy use and risk of invasive colon cancer. The California Teachers Study. Am J Epidemiol 171:415–425

    Article  Google Scholar 

  • Henderson VW, Paganini-Hill A, Miller BL et al. (2000) Estrogen for Alzheimer« disease. Neurology 54:295–301

    Article  PubMed  CAS  Google Scholar 

  • Hendrix SL, Cochrane BB, Nygaard IE et al. (2005) Effects of estrogen with and without progestin on urinary incontinence. JAMA 293:935–948

    Article  PubMed  CAS  Google Scholar 

  • Herrington DM et al. (2002) Factor V Leiden, hormone replacement therapy, and risk of venous thromboembolic events in women with cororary disease. Arterioscler Thromb Vasc Biol 22:1012–1017

    Article  PubMed  CAS  Google Scholar 

  • Study Group HERS (2003) Grady D et al.) Glycemic effects of postmenopausal hormone therapy. Ann Intern Med 138:1–9

    Article  Google Scholar 

  • Hulley S, Furberg C, Barrett-Connor E et al. (2002) Noncardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen/progestin Replacement Study Follop-up (HERS II). JAMA 288:49–57

    Article  PubMed  Google Scholar 

  • Hulley S, Grady D, Bush T, Furberg C et al. (1998) Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 280:605–613

    Article  PubMed  CAS  Google Scholar 

  • International Menopause Societey – IMS (2005) Guidelines zur Hormontherapie während und jenseits der Wechseljahre. Frauenarzt 46:96–101

    Google Scholar 

  • International Menopause Societey – IMS (2009a) Aktualisierte Empfehlungen zur Hormonersatztherapie in der Peri- und Postmenopause. J Gynäkol Endokrinol 19: 18–29

    Google Scholar 

  • International Menopause Societey – IMS (2009b) Workshop Consensus Group. Aging, menopause, cardiovascular disease and HRT. Climacteric 12:368–377

    Article  CAS  Google Scholar 

  • International Menopause Societey – IMS (2010) Empfehlungen zum Vorgehen bei postmenopausaler vaginaler Atrophie. J Gynäkol Endokrinol 13: 8–20

    Google Scholar 

  • Johnson JR, Lacey JV, Lazovich D et al. (2010) Menopausal hormone therapy and risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev 18: 196–203

    Article  Google Scholar 

  • Kenemans P (2005) Editorial. Maturitas 51:1–3

    Article  PubMed  Google Scholar 

  • Kenemans P, Bundred NJ, Foidart JM et al. (2009) Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomized, non-inferiority trial. Lancet Oncol 10:135–146

    Article  PubMed  CAS  Google Scholar 

  • Kenemans P, Speroff L (2005) Amsterdam Menopause Consensus Statement on Tibolone. Maturitas 51:21–28

    Article  PubMed  CAS  Google Scholar 

  • Krebs EE, Ensrud KE, MacDonald R, Wilt TJ (2004) Phytoestrogens for treatment of menopausal symptoms: a systematic review. Obstet Gynecol 104:824–836

    Article  PubMed  CAS  Google Scholar 

  • Kuhl H (2005) Breast cancer risk in the WHI study: The problem of obesity. Maturitas 51:83–97

    Article  PubMed  Google Scholar 

  • LeBlanc ES et al. (2001) Hormone replacement therapy and cognition: systematic review and meta-analysis. JAMA 285:1489–1499

    Article  PubMed  CAS  Google Scholar 

  • Lippert TH, Seeger H, Mueck AO (1999) Klinisch-pharmakologische Besonderheiten der konjugierten equinen Östrogene: Ist ihre Anwendung zur postmenopausalen Hormonsubstitution noch zeitgemäß? Arzneimitteltherapie 17:362–36

    Google Scholar 

  • Lokkegaard E, Andreasen AH, Jacobsen RK et al. (2008) Hormone therapy and risk of myocardial infarction: a national register study. Eur Heart J 29:2660–2668

    Article  PubMed  Google Scholar 

  • Lokkegaard E, Jovanovic Z, Heitmann BL (2003) Increased risk of stroke in hypertensive women using hormon therapy. Analyses based on the Danish Nurse Study. Arch Neurol 60: 1379–1384

    Article  PubMed  Google Scholar 

  • Lyytinen H, Pukkala E, Ylikorkala O (2009) Breast cancer risk in postmenopausal women using estradiol-progestogen therapy. Obstet Gynecol 113:65–73

    PubMed  Google Scholar 

  • Liu B et al.; Million Women Study Collaborators (2008) Gallbladder disease and use of transdermal versus oral hormone replacement therapy in postmenopausal women: prospective cohort study. Br Med J 337: 386

    Google Scholar 

  • MacLennan A, Lester S, Moore V (2001) Oral estrogen replacement therapy vs. placebo for hot flushes: a systematic review. Climacteric 4:58–74

    PubMed  CAS  Google Scholar 

  • MacLennan SC, MacLennan AH, Ryan P (1995) Colorectal cancer and oestrogen replacement therapy. A meta-analysis of epidemiologic studies. Med J Aust 162:491–493

    PubMed  CAS  Google Scholar 

  • Mikkola TS, Clarkson TB (2002) Estrogen replacement therapy, atherosclerosis, and vascular function. Cardiovascular Res 53:605–619

    Article  CAS  Google Scholar 

  • Miller J et al. (2002) Postmenopausal replacement and risk for venous thromboembolism: A systematic review and meta-analysis for the U.S. Peventive Service Task Force. Ann Intern Med 136:680–690

    Article  PubMed  CAS  Google Scholar 

  • Moehrer B, Hextall A, Jackson S (2003) Oestrogens for urinary incontinence in women. Cochrane Database Syst Rev 2: CD001405

    Google Scholar 

  • Mueck AO (2002) Arteriosklerose und Hormonsubstitution - Nutzen oder Risiken? Gynäkologe 35: 965–974

    Google Scholar 

  • Mueck AO (2003a) Primär- und Sekundärprävention kardiovaskulärer Erkrankungen durch Hormonsubstitution in der Postmenopause. Gynäkologe 36: 197–209

    Google Scholar 

  • Mueck AO (2003b) WHIMS – Risiko für Demenzen vascular verursacht? Geburtsh Frauenheilk 63:685–686

    Article  Google Scholar 

  • Mueck AO (2005) federführend für 6 gyn.-endokrinol Gesellschaften) Wirken kombinierte Kontrazeptiva und HRT karzinogen? Stellungnahme zur Bewertung der WHO Klassifizierung. Frauenarzt 47:740–742

    Google Scholar 

  • Mueck AO (2006a) Eine aktuelle Bewertung zur Sicherheit von Tibolon. Frauenarzt 47:832–839

    Google Scholar 

  • Mueck AO (2006b) Hormonersatztherapie bei internistischen Risikopatientinnen. Gynäkol Geburtsh Rundsch 46: 174–190

    Article  Google Scholar 

  • Mueck AO (2007) Behandlung von Hitzewallungen in der Peri- und Postmenopause bei Kontraindikationen für eine HRT. Gynäkologische Praxis 47:417–427

    Google Scholar 

  • Mueck AO (2010a) (federführend für 6 gyn.-endokrinol. Gesellschaften) Anwendungsempfehlungen für die gynäkologische Praxis zur Hormonsubstitution im Klimakterium und in der Postmenopause. DGGG, Berufsverband der Frauenärzte, Deutsche Menopause Gesellschaft, DGEGF, Dachverband Reproduktionsbiologie und -Medizin, Deutsche Gesellschaft für Senologie). Frauenarzt 2010; 52: 1023–1025

    Google Scholar 

  • Mueck AO (2010b) Exogenous hormones, the risk of venous thromboembolism, and activated protein C resistance. Editorial. Menopause 17(6): 1099–1102

    Article  Google Scholar 

  • Mueck AO, Römer T (Hrsg) (2002) Stoffwechsel und Hormonsubstitution. Thieme, Stuttgart, S 75–86

    Google Scholar 

  • Mueck AO, Seeger H (2003) Smoking, estradiol metabolism and hormone replacement therapy. Drug Research 53(1): 1–11

    PubMed  CAS  Google Scholar 

  • Mueck AO, Seeger H (2004a) Effect of hormone therapy on BP in normotensive and hypertensive women. Maturitas 49:189–203

    Article  CAS  Google Scholar 

  • Mueck AO, Seeger H (2004b) Hormone therapy and endometrial cancer. Endocrine Related Cancer 11:1–10

    Article  Google Scholar 

  • Mueck AO, Seeger H (2007a) Breast cancer: Are estrogen metabolites carcinogenic? Climacteric 10(Suppl 2): 62–65

    Article  CAS  Google Scholar 

  • Mueck AO, Seeger H (2007b) Kardiovaskuläre Risiken unter HRT in der Postmenopause. Gynäkol Endokrinologie 5: 120–126

    Article  CAS  Google Scholar 

  • Mueck AO, Seeger H (2008) The World Health Organization defines HRT as carcinogenic – is this plausible? Gynecol Endocrinol 24:129–132

    Article  PubMed  CAS  Google Scholar 

  • Mueck AO, Wallwiener D (2007) Brustkrebsrate und HRT-Verordnungen: Differierende Daten aus USA und Europa. Frauenarzt 48:812–816

    Google Scholar 

  • Mueck AO (für Berufsverband der Frauenärzte, BVF) (2004a) Änderungen der Zulassungen für die HRT. Frauenarzt 45:524

    Google Scholar 

  • Mueck AO, Kuhl H, Braendle W (für Deutsche Menopause G (2004b) Ergebnisse und Kommentare zu der WHI-Studie mit Estrogen-Monotherapie. Geburtsh Frauenheilkd 64:917–922

    Article  Google Scholar 

  • Mueck AO, Rabe T, Kiesel L (für Deutsche Gesellschaft für Gynäkologische Endokrinologie und Fortpflanzungsmedizin – DGGEF – und Deutsche Menopause Gesellschaft) (2006) HRT bei Patientinnen nach Mammakarzinom. J Reproduktionsmed Endokrinol 3: 145–153

    Google Scholar 

  • Mueck AO, Seeger H, Shapiro S (2010) Risk of breast cancer during hormone replacement therapy: Mechanisms. Horm Mol Biol Clin Invest 3:329–339

    Google Scholar 

  • Mulnard RA, Cotman CW, Kawas C et al. (2000) Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease. JAMA 283:1007–1015

    Article  PubMed  CAS  Google Scholar 

  • Munster PN, Carpenter JT (2009) Estradiol in breast cancer treatment. Reviving the past. JAMA 302:797–798

    Article  PubMed  CAS  Google Scholar 

  • Naessen T, Rodriguez-Macias K (2001) Serum lipid profile improved by ultra low doses of 17ß estradiol in elderly women. J Clin Endocrinol Metab 86:2757–62

    Article  PubMed  CAS  Google Scholar 

  • North American Menopause Society – NAMS (2010a) North American Menopause Society) Estrogen and progestogen use in postmenopausal women. Menopause 17:242–255

    Article  Google Scholar 

  • North American Menopause Society – NAMS (2010b) North American Menopause Society) Management of osteoporosis in postmenopausal women. Menopause 17:25–54

    Article  Google Scholar 

  • North American Menopause Society – NAMS (2000a) The role of isoflavones in menopausal health: Consensus Opinion. Menopause 7:215–229

    Article  Google Scholar 

  • North American Menopause Society – NAMS (2000b) NAMS Consensus Opinion. North American Menopause Society. Effects of menopause and estrogen replacement therapy or hormone replacement therapy in women with diabetes mellitus. Menopause 7:87–95

    Article  Google Scholar 

  • Nanda K et al. (2002) Hormone replacement therapy and the risk of death from breast cancer: a systematic review. Am J Obstet Gynecol 186:325–334

    Article  PubMed  CAS  Google Scholar 

  • Nanda K, Bastian LA, Hasselblad V, Simel DL (1999) Hormone replacement therapy and the risk of colorectal cancer: a meta-analysis. Obstet Gynecol 93:880–888

    Article  PubMed  CAS  Google Scholar 

  • Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD (2002) Postmenopausal hormone replacement therapy. JAMA 288:872–881

    Article  PubMed  CAS  Google Scholar 

  • Opatrny L, Dell’Aniello S, Assouline S, Suissa S (2008) Hormone replacement therapy and variations in the risk of breast cancer. Br J Obstet Gynecol 115:169–175

    CAS  Google Scholar 

  • Ortmann O (federführend); Deutsche Gesellschaft für Gynäkologie und Geburtshilfe – DGGG (2009) Leitlinie S3. Hormontherapie in der Peri- und Postmenopause. a) Kurzversion der interdisziplinären S3-Leitlinie. Frauenarzt 50: 840–851, b) Langversion [http://www.dggg.de] – Leitlinie HRT, AWMF-Leitlinien-Registrier-Nr. 015/062

  • Ortmann O, Lattrich C, Diedrich K (2010) Hormontherapie in der Peri- und Postmenopause. Risikoberatung. Gynäkologe 10: 839–846

    Google Scholar 

  • Petru E, Benedicic C (2004) Phytoöstrogene: Potentiell ungünstige Effekte. Frauenarzt 45:536–541

    Google Scholar 

  • Ragaz J, Wilson K, Muraca G et al. (2010) Endogenous estrogen stimulates, exogenous estrogen protects. Further investigation of estrogen chemoprevention is warranted. Poster P6–09-09, Abstract No 1410 presented at the 2010 San Antonio Breast Cancer Symposium

    Google Scholar 

  • Rapp SR et al. (2003) Effect of estrogen plus progestin on global cognitive function in postmenopausal women. The Women’s Health Initiative Memory Study. JAMA 289:2663–2672

    Article  PubMed  CAS  Google Scholar 

  • Renoux C, Dell-Aniello S, Garbe D, Suissa S (2010a) Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study. Br Med J 340: c2519

    Google Scholar 

  • Renoux C, Dell-Aniello S, Suissa S (2010b) Hormone replacement therapy and the risk of venous thromboembolism: a population-based study. J Thrombosis Haemostasis 8:979–986

    CAS  Google Scholar 

  • Resnick SM, Henderson VW (2002) Hormone therapy and risk of Alzheimer disease: a critical time. JAMA 288:2170–2172

    Article  PubMed  Google Scholar 

  • Sacket DL (1996) Evidence-based Medicine – what it is and what it isn’t. Br Med J 312:71–13

    Article  Google Scholar 

  • Salpeter SR, Buckley NS, Liu H, Salpeter EE (2009a) The costeffectiveness of hormone therapy in younger and older postmenopausal women. Am J Mede 122:42–52

    Article  Google Scholar 

  • Salpeter SR, Chen J, Thabane L et al. (2009b) Bayesian metaanalysis of hormone therapy and mortality in younger postmenopausal women. Am J Med 122:1016–1022

    Article  CAS  Google Scholar 

  • Salpeter SR, Walsch JME, Greyber E, Salpeter EE (2006a) Coronary heart disease events associated with hormone therapy in younger and older women. A Meta Analysis. J Gen Intern Med 21:401–410

    Article  Google Scholar 

  • Salpeter SR, Walsh JM, Greyber E et al. (2004) Mortality associated with hormone replacement therapy in younger and older women: a meta-analysis. J. Gen Intern Med 19:791–80

    Article  Google Scholar 

  • Salpeter SR, Walsh JM, Greyber E et al. (2006b) Coronary heart disease events associated with hormone therapy in younger and older women. A meta analysis. J Gen Intern Med 21:401–410

    Article  Google Scholar 

  • Santen RJ et al. (2010) Endocrine Society scientific statement. J Clin Endorinol Metab 95(Suppl 1): S1–S66

    Article  CAS  Google Scholar 

  • Scarabin PY, Oger E, Plu-Bureau G (2003) Differential association of oral and transdermal oestrogen replacement therapy with venous thromboembolism risk. Lancet 362:428–432

    Article  PubMed  CAS  Google Scholar 

  • Schneider C, Jick SS, Meier CR (2009) Risk of gynecological cancers in users of estradiol/dydrogesterone or other HRT preparations. Climacteric 12:514–524

    Article  PubMed  CAS  Google Scholar 

  • Seeger H, Mueck AO (2008a) HRT and breast cancer: Caused by progestogens? Experimental vs. clinical data. J Steroid Biochem Mol Biol 109:11–15

    Article  CAS  Google Scholar 

  • Seeger H, Mueck AO (2008b) HRT and breast cancer: Caused by progestogens? Experimental vs. clinical data. J Steroid Biochem Mol Biol 109:11–15

    Article  CAS  Google Scholar 

  • Seeger H, Wallwiener D, Krämer E, Mueck AO (2006) Comparison of possible carcinogenic estradiol metabolites: Effects on proliferation, apoptosis and metastasis of human breast cancer cells. Maturitas 54:72–77

    Article  PubMed  CAS  Google Scholar 

  • Seibel MJ (2001) Evaluation des osteoporotischen Frakturrisikos. Dt Ärztebl 25: A1681–A1689

    Google Scholar 

  • Shah NR, Borenstein J, Dubois RW (2005) Postmenopausal hormone therapy and breast cancer: a systematic review and meta-analysis. Menopause 12:668–678

    Article  PubMed  Google Scholar 

  • Shapiro S (2003) Risks of estrogen plus progestin therapy: a sensitivity analysis of findings in the Women’s Health Initiative randomized controlled trial. Climacteric 6:302–310

    PubMed  CAS  Google Scholar 

  • Shapiro S (2004) The Million Women Study: potential biases do not allow uncritical acceptance of the data. Climacteric 7:3–7

    Article  PubMed  Google Scholar 

  • Shapiro S, Farmer R, Seaman H, Stevenson J, Mueck AO (2011) Does hormone replacement therapy cause breast cancer? An application of causal principles to three studies. Part 1: The Collaborative Reanalysis. J Fam Plann Reprod Health Care 37(2): 103–109

    Article  PubMed  Google Scholar 

  • Shumaker SA et al. (2003) Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women. The Women’s Health Initiative Memory Study. JAMA 289:2651–2662

    Article  PubMed  CAS  Google Scholar 

  • Straczek C et al. (2005) for the ESTHER Study Group) Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women. Impact of the route of estrogen administration. Circulation 112:3495–3500

    Article  PubMed  CAS  Google Scholar 

  • THEBES Study Group; Archer DF et al. (2007) Endometrial effects of tibolone. J Clin Endocrinol Metab 92:911–918

    Article  PubMed  CAS  Google Scholar 

  • Torgerson DJ, Bell-Syer SEM (2001) Hormone replacement therapy and prevention of nonvertebral fractures. A meta-analysis of randomized trials. JAMA 285:2891–2897

    Article  PubMed  CAS  Google Scholar 

  • Weisberg E, Ayton R, Darling G et al. (2005) Endometrial and vaginal effects of low dose estradiol delivered by vaginal ring or vaginal tablet. Climacteric 8:23–92

    Article  CAS  Google Scholar 

  • WHI Investigators; Chlebowski RT et al. (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288:321–333

    Article  Google Scholar 

  • WHI Investigators; Chlebowski RT et al. (2003a) Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women. JAMA 289:3243–3253

    Article  CAS  Google Scholar 

  • WHI Investigators; Manson JE et al. (2003b) Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003; 349: 523–534

    Google Scholar 

  • Investigators WHI (2004a) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. JAMA 291:1701–1712

    Article  Google Scholar 

  • WHI Investigators; Cushman M et al. (2004b) Estrogen plus progestin and risk of venous thrombosis. JAMA 292:1573–1580

    Article  CAS  Google Scholar 

  • Investigators WHI (2004c) Lower incidence of diabetes seen among hormone therapy users in Women’s Health Initiative. Diabetologica 47:1175–1187

    Google Scholar 

  • WHI Investigators; Curb JD et al. (2006a) Venous thrombosis and conjugated equine estrogens in women without a uterus. Arch Intern Med 2006; 166: 772–780

    Article  CAS  Google Scholar 

  • WHI Investigators; Hsia J et al. (2006b) Conjugated equine estrogens and coronary heart disease. Arch Intern Med 166:357–365

    Article  CAS  Google Scholar 

  • WHI Investigators; Stephanick ML et al. (2006c) Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 295:1647–57

    Article  Google Scholar 

  • WHI Investigators; Manson JE et al. (2007a) Estrogen therapy and coronary-artery calcification. n Engl J Med 356:2591–2602

    Article  CAS  Google Scholar 

  • WHI Investigators; Rossouw J et al. (2007b) Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 297:1465–1477

    Article  CAS  Google Scholar 

  • WHI Investigators; Heiss G et al. (2008) Health risks and bene- fits 3 years after stop** randomized treatment with estrogen and progestin. JAMA 299:1036–1045

    Article  PubMed  CAS  Google Scholar 

  • WHI Investigators; Chlebowski RT et al. (2009) Breast cancer after use of estrogen plus progestin in postmenopausal women. n Engl J Med 360:573–587

    Article  PubMed  CAS  Google Scholar 

  • Whitmer RA, Quesenberry CP, Zhou Y, Yaffe K (2011) Timing of hormone therapy and dementia: the critical window theory revisited. Ann Neurol 69(1): 163–169

    Article  PubMed  Google Scholar 

  • Windler E, Mueck AO, Zyriax BC, Ortmann O (2010) Herz-Kreislauf-Risiko und Hormontherapie in der Postmenopause. Gynäkologe 43: 301–307

    Article  CAS  Google Scholar 

  • Witteman JCM, Grobbee DE, Kok FJ et al. (1989) Increased risk of atherosclerosis in women after the menopause. Br Med J 298:642–644

    Article  CAS  Google Scholar 

  • Wuttke W, Jarry H, Westphalen S et al. (2002) Phytoöstrogene – eine Alternative zur Standard-Hormonersatztherapie? Gynäkologe 35: 1007–1020

    Google Scholar 

  • Yaffe K, Sawaya G, Lieberburg I, Grady D (1998) Estrogen therapy in postmenopausal women. Effects on cognitive function and dementia. JAMA 279:688–695

    Article  PubMed  CAS  Google Scholar 

  • Zandi PP, Carlson MC, Plassman BL et al. (2002) Hormone replacement therapy and incidence of Alzheimer Disease in older women. The Cache County Study. JAMA 288:21232129

    Article  Google Scholar 

  • Ziller V, Hadji P (2010) Leitliniengerechte Diagnostik und Therapie der Osteoporose – State of the Art. Pharma Fokus Gynäkol 5: 17–22

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Universitätsfrauenklinik Tübingen, Schwerpunkt für Endokrinologie und Menopause, Calwer Straße 7, 72076, Tübingen

    Prof. Dr. med. Dr. rer. nat. Alfred O. Mueck

Authors
  1. Prof. Dr. med. Dr. rer. nat. Alfred O. Mueck
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Fürst-Stirum-Klinik Bruchsal, Frauenklinik, Gutleutstraße 1–14, 76646, Bruchsal

    Jürgen Wacker

  2. Praxisklinik am Rosengarten, Augustaanlage 7–11, 68165, Mannheim

    Martin Sillem

  3. Praxisklinik am Rosengarten, Augustaanlage 7–11, 68165, Mannheim

    Gunther Bastert

  4. Universitätsklinikum Erlangen-Nürnberg, Frauenklinik, Universitätsstraße 21–23, 91054, Erlangen

    Matthias W. Beckmann

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Mueck, A. (2013). Hormonersatztherapie. In: Wacker, J., Sillem, M., Bastert, G., Beckmann, M. (eds) Therapiehandbuch Gynäkologie und Geburtshilfe. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-30189-6_28

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-30189-6_28

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-30188-9

  • Online ISBN: 978-3-642-30189-6

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation